Remove Clinical Supply Chain Remove Clinical Trials Remove Manufacturing
article thumbnail

Untangling the Complexities of Cell and Gene Therapy Clinical Trials: A Supply Chain Perspective 

Pharmaceutical Technology

By Luisa Sterkel & Joana Loureiro , Tenthpin Consultants The promise and potential of cell and gene therapies (CGT) has emerged in the recent past and currently over 1.500 CGT are registered for clinical trials holding great hope for the treatment of challenging and uncurable diseases.

article thumbnail

Signant clinical supply chain software offers end-to-end visibility

Outsourcing Pharma

SmartSignals Supplies is designed to help trial teams get a handle on clinical trial supply chain management to avoid delays, waste, and cost overruns.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How to plan for uncertainty while maximizing the efficiency of your clinical sup…

The Pharma Data

Supply chain uncertainty is a challenge every clinical supply chain manager wrestles with – stemming from increasing product demand and quality, the growing complexity of clinical trial designs and a lack of visibility in the supply chain.

article thumbnail

AWS helps Pfizer accelerate drug development and clinical manufacturing

The Pharma Data

company (NASDAQ: AMZN), announced that it is working with Pfizer to create innovative, cloud-based solutions with the potential to improve how new medicines are developed, manufactured, and distributed for testing in clinical trials. (AWS), an Amazon.com, Inc.

article thumbnail

Why demand is rising for secure and climate-controlled gene therapy services

Pharmaceutical Technology

According to GlobalData’s clinical trials database, there are currently 1,231 planned and ongoing trials for gene therapies and gene-modified cell therapies alone. Cell and gene therapies are not your typical clinical supply chain.

article thumbnail

The Chemotherapy Drug Shortage: An Unprecedented Crisis

XTalks

Concerningly, the survey also revealed that only 40 percent of the surveyed NCCN cancer centers received any indication from manufacturers or suppliers about when carboplatin or cisplatin would be readily available again. These drugs are often generics and hence have a low unit price, making them less appealing to manufacturers.

Drugs 98